ANTX
AN2 Therapeutics Inc

368
Loading...
Loading...
News
all
press releases
Centene stock tumbles after withdrawal of 2025 guidance
Investing.com -- Centene Corporation (NYSE:CNC) stock tumbled 20% after the health insurer withdrew its 2025 earnings guidance, citing unexpected challenges in its Health Insurance Marketplace business and rising Medicaid costs.
investing.com·3mo ago
News Placeholder
More News
News Placeholder
As UnitedHealth tumbles, one competitor said they are doing fine
Investing.com -- UnitedHealth (NYSE:UNH) sent shockwaves throughout the managed care sector Thursday after posting weak first quarter results and lowering its full year guidance.  However, for at least one competitor, it is not a “we” problem but a “you” problem.
investing.com·6mo ago
News Placeholder
AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced...
Business Wire·7mo ago
News Placeholder
AN2 Therapeutics to Participate at Upcoming Investor Conferences
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced...
Business Wire·7mo ago
News Placeholder
AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced...
Business Wire·8mo ago
News Placeholder
Elevance Health Q4 earnings miss estimates, stock rises
Investing.com -- Elevance Health Inc. reported fourth quarter earnings that missed analyst expectations, but the health insurer's shares rose following the release.
investing.com·8mo ago
News Placeholder
AN2 Therapeutics to Participate at Upcoming Investor Conferences
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced...
Business Wire·11mo ago
News Placeholder
AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported...
Business Wire·11mo ago
News Placeholder
AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced...
Business Wire·1y ago
News Placeholder
AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced...
Business Wire·1y ago

Latest ANTX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.